Ortoma AB Series B (ORT-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ortoma AB Series B (ORT-B) has a cash flow conversion efficiency ratio of -0.120x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-17.13 Million ≈ $-1.84 Million USD) by net assets (Skr142.72 Million ≈ $15.36 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ortoma AB Series B - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Ortoma AB Series B's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ORT-B liabilities breakdown for a breakdown of total debt and financial obligations.
Ortoma AB Series B Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ortoma AB Series B ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Acanthe Développement
PA:ACAN
|
-0.049x |
|
Resource Mining Corporation Ltd
AU:RMI
|
-0.078x |
|
EYG Gayrimenkul Yatirim Ortakligi A.S.
IS:EYGYO
|
0.020x |
|
George Kent (Malaysia) Bhd
KLSE:3204
|
0.037x |
|
Medicamen Biotech Limited
NSE:MEDICAMEQ
|
0.013x |
|
Orient Precision Industries Inc
KQ:065500
|
-0.015x |
|
Yotta Acquisition Corporation Common Stock
NASDAQ:YOTA
|
-0.116x |
|
Bubang Co. Ltd
KQ:014470
|
0.043x |
Annual Cash Flow Conversion Efficiency for Ortoma AB Series B (2021–2025)
The table below shows the annual cash flow conversion efficiency of Ortoma AB Series B from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see Ortoma AB Series B (ORT-B) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr142.72 Million ≈ $15.36 Million |
Skr6.04 Million ≈ $649.78K |
0.042x | +131.12% |
| 2024-12-31 | Skr161.91 Million ≈ $17.42 Million |
Skr-22.01 Million ≈ $-2.37 Million |
-0.136x | -276.65% |
| 2023-12-31 | Skr173.54 Million ≈ $18.68 Million |
Skr13.35 Million ≈ $1.44 Million |
0.077x | +206.13% |
| 2022-12-31 | Skr114.29 Million ≈ $12.30 Million |
Skr-8.29 Million ≈ $-891.82K |
-0.073x | +37.94% |
| 2021-12-31 | Skr130.04 Million ≈ $13.99 Million |
Skr-15.19 Million ≈ $-1.63 Million |
-0.117x | -- |
About Ortoma AB Series B
Ortoma AB (publ) provides orthopedic surgical products in Sweden. It offers Ortoma Treatment Solution (OTS), an orthopedic digital, server-based integrated AI platform designed to optimize patient outcomes through surgical planning, precision surgical navigation, post-operative verification, and follow-up; OTS Plan, a software that processes and assists surgeons during pre-operative planning and … Read more